+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Intratympanic dexamethasone for profound idiopathic sudden sensorineural hearing loss



Intratympanic dexamethasone for profound idiopathic sudden sensorineural hearing loss



Otolaryngology--Head and Neck Surgery 132(6): 902-905



To determine hearing recovery by using intratympanic dexamethasone for profound, idiopathic sudden sensorineural hearing loss (ISSNHL). A prospective, clinical study was performed of 25 consecutive patients seen with profound ISSNHL. Patients received 4 intratympanic treatments of dexamethasone over the course of 2 weeks. Complete hearing recovery was defined as the final pure-tone average (PTA) within 10 dB of baseline. Partial recovery was defined as a final PTA with >/=50% hearing. The hearing in the contralateral ear was used as baseline. The average time to treatment was 28 days. Two patients had significant hearing recovery, and 1 additional patient had partial recovery. The 2 patients with significant hearing recovery were treated within 9 days of onset of hearing loss. By using the treatment protocol and definition of hearing recovery of this study, intratympanic dexamethasone does not result in significant hearing improvement for patients with profound ISSNHL. There is a possible trend for improved hearing results if intratympanic treatment is performed within 11 days of onset of hearing loss.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 049396110

Download citation: RISBibTeXText

PMID: 15944562

DOI: 10.1016/j.otohns.2005.01.024


Related references

Intratympanic steroid administration: use in the treatment of profound idiopathic sudden sensorineural hearing loss. Hno 61(2): 152, 154-8, 2013

Intratympanic steroids as a salvage therapy for severe to profound idiopathic sudden sensorineural hearing loss. Acta Oto-Laryngologica 2018: 1-6, 2018

Intratympanic methylprednisolone perfusion as a salvage treatment for profound idiopathic sudden sensorineural hearing loss. Journal of Laryngology and Otology 131(5): 404-410, 2017

Randomized, double blind, placebo controlled trial on the safety and efficacy of continuous intratympanic dexamethasone delivered via a round window catheter for severe to profound sudden idiopathic sensorineural hearing loss after failure of systemic therapy. Laryngoscope 119(2): 359-369, 2009

Primary treatment of idiopathic sudden sensorineural hearing loss with intratympanic dexamethasone. Current Opinion in Otolaryngology and Head and Neck Surgery 24(5): 407-412, 2018

Intratympanic Dexamethasone via Saturated Gelfoam for Idiopathic Sudden Sensorineural Hearing Loss. Otolaryngology--Head and Neck Surgery 2018: 194599818816306, 2018

Simultaneous versus subsequent intratympanic dexamethasone for idiopathic sudden sensorineural hearing loss. Otolaryngology--Head and Neck Surgery 145(6): 1016-1021, 2012

Dose Effect of Intratympanic Dexamethasone for Idiopathic Sudden Sensorineural Hearing Loss: 24 mg/mL Is Superior to 10 mg/mL. Otology and Neurotology 36(8): 1321-1327, 2016

Intratympanic Dexamethasone after High-Dose Intravenous Methylprednisolone in Idiopathic Sudden Sensorineural Hearing Loss. Otolaryngology - Head and Neck Surgery 151(1 Suppl): P88-P88, 2014

Intratympanic Methylprednisolone versus Dexamethasone for the Primary Treatment of Idiopathic Sudden Sensorineural Hearing Loss. Journal of International Advanced Otology 2018, 2018

The effect of intratympanic dexamethasone with oral prednisolone as a primary treatment in idiopathic sudden sensorineural hearing loss. Iranian Journal of Otorhinolaryngology 24(66): 19-22, 2012

The Role of High Dose Intratympanic Dexamethasone as Salvage Therapy for Idiopathic Sudden Sensorineural Hearing Loss. Journal of International Advanced Otology 13(3): 318-321, 2017

Combined therapy (intratympanic dexamethasone + high-dose prednisone taper) for idiopathic sudden sensorineural hearing loss. Otology and Neurotology 30(2): 254-5; Author Reply 255-6, 2008

Intratympanic dexamethasone as initial therapy for idiopathic sudden sensorineural hearing loss: Clinical evaluation and laboratory investigation. Auris, Nasus, Larynx 38(2): 165-171, 2011

Efficacy of low-dose intratympanic dexamethasone as a salvage treatment for idiopathic sudden sensorineural hearing loss: the Modbury Hospital experience. Journal of Laryngology and Otology 128 Suppl 2: S27-S30, 2015